Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:30 PM
Ignite Modification Date:
2025-12-24 @ 1:30 PM
NCT ID:
NCT03853395
Eligibility Criteria:
Inclusion Criteria:
1. Patients with RA about to start therapy with adalimumab or certolizumab
2. Age 18 and over, male or female
3. Willing to take part in the study
4. Patients who consent to take part in the BRAGGSS study
Exclusion Criteria:
1. Patients unwilling or unable to take part in the study
2. Pregnant women or nursing (breast feeding) mothers.
3. Planned pregnancy within next 12 months.
4. Scheduled surgery in the next 12 months or other pre-planned reasons for treatment discontinuation in the next 12 months.
5. Contraindication to adalimumab or certolizumab according to the summary of product characteristics
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03853395
Study Brief:
Protocol Section:
NCT03853395